Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | S100A4 | P26447 | 2/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30398320 | 1.00 | MAPT (0.50) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL6383602 | 0.81 | MAPT (0.62) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL9202289 | 0.81 | CACNA1C (0.42) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL1116123 | 0.79 | NPSR1 (0.42) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL14452741 | 0.77 | MAPT (0.53) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL7823572 | 0.77 | MAPT (0.50) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL12834635 | 0.77 | MAPT (0.40) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL8948751 | 0.75 | MAPT (0.43) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL12856296 | 0.75 | MAPT (0.44) | MAPTKMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL6974946 | 0.74 | MAPT (0.40) | MAPTKMT2AMEN1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-06-12 | — | — | US | disclosed |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | NOVARTIS AG (CH) | 2025-04-29 | — | — | US | disclosed |
| US-20250090491-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| US-12083092-B2 | Antiviral 1,3-di-oxo-indene compounds | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| CN-115916763-A | Antivirals 1, 3-dioxoindene compounds | 诺华股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115867545-A | Antiviral 1,3 dioxoindene compounds | 诺华股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-4139290-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | Novartis AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| EP-4139301-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | Novartis AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214080-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214073-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| US-20210322362-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| US-20210322362-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| EP-0566063-A1 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322362-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, MAVS | MAPT 3170/4885KMT2A 4680/4885MEN1 1670/4885 |
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | MAPT 3288/4885KMT2A 4549/4885MEN1 1786/4885 |
| US-20250090491-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, MAVS | MAPT 3170/4885KMT2A 4680/4885MEN1 1670/4885 |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | MAPT 3288/4885KMT2A 4549/4885MEN1 1786/4885 |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | IRF3, EIF2AK2, ZC3HAV1 | MAPT 3288/4885KMT2A 4549/4885MEN1 1786/4885 |
| US-12083092-B2 | Antiviral 1,3-di-oxo-indene compounds | IRF3, EIF2AK2, MAVS | MAPT 3170/4885KMT2A 4680/4885MEN1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.